SCHEMBL29042371

SCHEMBL29042371

CC1(C)OC(c2ccc3cc[nH]c3c2)OC1(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ AHR P35869 4/20 0.42
▸ CMA1 P23946 1/20 0.42
▸ TYR P14679 1/20 0.42
▸ SLC6A2 P23975 2/20 0.41
▸ SLC6A4 P31645 2/20 0.41
▸ SLC6A3 Q01959 2/20 0.41
▸ ENPP2 Q13822 2/20 0.39
▸ CYP2A6 P11509 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ BRD4 O60885 1/20 0.37
▸ GPR84 Q9NQS5 1/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.34
▸ TRPA1 O75762 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29042384 0.87 AHR (0.42) AHRSLC6A2SLC6A4SLC6A3CYP2A6
SCHEMBL17863581 0.71 MAPK1 (0.37) MEN1MAPK1KMT2A
SCHEMBL15566771 0.71 AHR (0.50) MEN1POLBMAPK1KMT2AAHR
SCHEMBL17913415 0.70 AHR (0.46) MEN1POLBMAPK1KMT2AAHR
SCHEMBL7864936 0.70 TNKS (0.43) MAPK1BRD4
SCHEMBL19235056 0.68 MEN1 (0.47) MEN1POLBMAPK1KMT2AAHR
SCHEMBL30286426 0.68 NOS1 (0.45) MEN1POLBKMT2ASLC6A2SLC6A4
SCHEMBL17014397 0.67 NPC1 (0.58) KDM4EALDH1A1L3MBTL1CYP2D6
SCHEMBL9946120 0.67 HTR2A (0.37) ALDH1A1TDP1ESR1
SCHEMBL13718 0.67 LPL (0.46) MEN1POLBMAPK1KMT2AAHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115279741-A 4-phenyl-N- (phenyl) thiazol-2-amine derivatives and related compounds as Aryl Hydrocarbon Receptor (AHR) agonists for the treatment of, for example, angiogenesis-related disorders or inflammatory disorders 医肯纳肿瘤学公司 2022-11-01 — — CN disclosed
Send feedback